Abstract: The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof.

Abstract: Stabilized porous silicon particles are disclosed. The particles include a porous silicon particle comprising a plurality of interconnected silicon nanoparticles and (i) a heterogeneous layer comprising a discontinuous SiC coating that is discontinuous across a portion of pore surfaces and across a portion of an outer surface of the porous silicon particle, and a continuous carbon coating that covers outer surfaces of the discontinuous SiC coating, and remaining portions of the pore surfaces and the outer surface of the porous silicon particle, or (ii) a continuous carbon coating on surfaces of the porous silicon particle, including the outer surface and pore surfaces. Methods of making the stabilized porous silicon particles also are disclosed.

Abstract: The present invention provides a handheld sweeping and mopping structure, comprising a handle and a body shell, wherein a sweeping and mopping module, a water tank module, a driving module, a garbage collection module, a control module and a power supply module are provided inside the body shell. The handheld sweeping and mopping structure of the present invention can sweep the floor and also mop the floor, has higher efficiency and better effect than the conventional sweeping and mopping mode; and meanwhile, a disposable garbage box which is convenient to replace is used, and it is unnecessary to clean the garbage box repeatedly.

Abstract: Disclosed are a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.

Abstract: Provided in the present invention is a method for constructing a high-resolution single cell Hi-C library with a large amount of information, comprising the following steps: Step B: obtain a small amount of fixed chromatin; Step C: digest the fixed chromatin in Step B to obtain fragments of the fixed chromatin; Step D: reconnect the fragments of the fixed chromatin in Step C directly to obtain reconnected fragments of the fixed chromatin; Step E: de-fix the reconnected fragments of the fixed chromatin in Step D to release DNA fragments; Step F: amplify the released DNA fragments in Step E to obtain amplified products; and Step H: construct a sequencing DNA library by using the amplified products as the DNA fragments to be sequenced.

Abstract: Disclosed is a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.

Abstract: This application relates to the field of communications technologies, and in particular, to a profile download technology. In a profile download method, a primary device obtains an embedded integrated circuit card identifier (EID) of a secondary device, where the EID is used by the primary device to obtain, from a mobile operator server, profile download information that matches the EID; receives the profile download information from the mobile operator server; and sends the profile download information to the secondary device, where the profile download information is used by the secondary device to download a profile from a profile management server, and the profile is installed in an embedded UICC (eUICC) of the secondary device after the download is complete.

Abstract: Disclosed is a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.

Abstract: This application relates to the field of communications technologies, and in particular, to a profile download technology. In a profile download method, a primary device obtains an embedded integrated circuit card identifier (EID) of a secondary device, where the EID is used by the primary device to obtain, from a mobile operator server, profile download information that matches the EID; receives the profile download information from the mobile operator server; and sends the profile download information to the secondary device, where the profile download information is used by the secondary device to download a profile from a profile management server, and the profile is installed in an embedded UICC (eUICC) of the secondary device after the download is complete.

Abstract: Disclosed are a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.

Abstract: Disclosed is a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.

Abstract: Disclosed is a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.

Abstract: Disclosed are a lanosterol prodrug compound, a pharmaceutically acceptable salt and an isomer thereof, and a pharmaceutical composition comprising the lanosterol prodrug compound and the use thereof in the preparation of a drug for treating cataracts. The lanosterol prodrug compound has a better permeability than lanosterol.

Abstract: Disclosed are a crystalline or amorphous form of steroid derivative FXR agonist (formula I), and a preparation method therefor, and a crystalline composition and pharmaceutical composition comprising the crystalline or amorphous form, and the use of same in the preparation of a drug for treating or preventing various conditions associated with FXR.

Abstract: The present invention falls within the field of pharmaceutical chemistry, and relates to a method for preparing a steroid derivative FXR agonist and relevant intermediates. In particular, the present invention relates to a method for preparing a compound of formula I, comprising reacting a compound of formula 8 with a compound of formula 9 to obtain a compound of formula 10, obtaining a compound of formula 11 from a reaction of the compound of formula 10, and obtaining the compound of formula I from a reaction of the compound of formula 11, as well as the intermediates used, the methods for preparing the intermediates and the use of the intermediates. The reaction conditions of the preparation method are mild, and some of the steps can convert multiple groups simultaneously, thereby effectively shortening the sequence of steps. The preparation method is suitable for industrialized production.

Abstract: A sodium-ion battery that includes an anode comprising hard carbon and lithium; and an electrolyte composition comprising an ether solvent and a sodium salt.

Abstract: Computer program products, methods, systems, apparatus, and computing entities provide a unique single-shot text detector that generates word-level text bounding boxes in an image by at least identifying text regions in the image via an automatically learned attention map and by conducting pixel-wise review of text; aggregating multi-scale inception features; generating, based at least in part on the multi-scale inception features, a set of aggregated inception features; and generating, using at least the set of aggregated inception features, the word-level text bounding boxes in the image.

Abstract: Disclosed are a preparation method of an orexin receptor antagonist compound 5-3, Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of the preparing the orexin receptor antagonist compound 5-3 and its crystalline forms, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.

Abstract: An anode active material comprises a silicon-carbon secondary particle comprising a composite having an exterior conformal carbon coating and formed of type I primary particles. Each type I primary particle comprises a core particle of interconnected silicon, the interconnected silicon formed of nano-sized silicon particles each connected to at least one other particle, inner pores internal to the core particle and defined by the interconnected silicon, an internal carbon coating on internal wall surfaces of the inner pores and a conformal carbon coating on the core particle.

Abstract: Methods and systems disclosed herein utilize an automated analytics framework to implement a perioperative complication risk algorithm that uses existing clinical data in electronic health records to forecast patient-level probabilistic risk scores for eight major postoperative complications. An example method includes accessing health record data for a patient, normalizing the accessed health record data to generate a health record data set for the patient, transforming one or more features from the health record data set, selecting one or more transformed features from the health record data set, calculating risk probabilities for one or more complication risk categories based on the health record data set and the selected one or more features, calculating mortality risk probabilities for one or more mortality risk categories based on the calculated risk probabilities, and generating a personalized risk panel based on the calculated risk probabilities and the calculated mortality risk probabilities.